Moderna Inc today announced that the independent NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has shown that the company's experimental vaccine is 94.5% effective in preventing novel coronavirus. The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. Moderna's first analysis was based on 95 cases of COVID-19, 90 of which received a placebo with 5 receiving the vaccine. The results come one week after Pfizer Inc and German partner BioNTech SE said their experimental vaccine was more than 90% effective based on initial data. Scientists have warned for months that any COVID-19 shot may be only as good as flu vaccines, which are about 50% effective.

Source: Mint November 16, 2020 12:06 UTC